APMD Stock Forecast: Apnimed, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Apnimed, Inc. is $50. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 4 of 100 as at 21 Nov 2026 — in the weakest quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Apnimed, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (57): Analysts have, on balance, been raising their forecasts.
Issuance (4): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
APMD stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on APMD, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 25 Aug 2026 | B of A Securities | Initiates | Buy | $41 |
| 25 Aug 2026 | Cantor Fitzgerald | Initiates | Overweight | $60 |
| 25 Aug 2026 | Evercore ISI Group | Initiates | Outperform | — |
| 25 Aug 2026 | LifeSci Capital | Initiates | Outperform | $50 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for APMD.
This page is one stock. Monday covers all of them.
APMD appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
APMD vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
APMD analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 1.2×
- Price / sales
- 6.2×
- Price / book
- —
- EV / EBITDA
- 29.7×
Cheaper than 92% of US stocks
Cheaper than 18% of US stocks
Cheaper than 11% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- 90.0%
- Operating margin
- 11.4%
- Net margin
- —
Higher than 96% of US stocks
Higher than 66% of US stocks
- Return on equity
- —
- Return on assets
- −1.3%
- Dividend yield
- —
Higher than 39% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Apnimed, Inc. has a market value of $669.8M and an enterprise value of $368.1M.
Trailing P/E: 1.2×.
Apnimed, Inc. employs 112 people.
Data provided by Twelve Data
APMD and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at APMD’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Apnimed, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about APMD
What is the APMD stock price forecast for 2026-2027?
The median 12-month analyst price target for Apnimed, Inc. is $50, with estimates ranging from $40 to $60. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is APMD stock a buy right now?
Of the 4 analysts covering Apnimed, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Apnimed, Inc. 4 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank APMD?
As at 21 Nov 2026, Apnimed, Inc. ranks 4 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (57 of 100).
Will APMD stock go up?
No one can know that. What the data says: the median 12-month target from 4 analysts is $50, and Ticker Nerd's factor model ranks Apnimed, Inc. 4 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the APMD stock forecast for 2030?
No analyst covering Apnimed, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for APMD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $40 to $60 over the next 12 months.
What does Apnimed, Inc. do?
Apnimed, Inc. is a clinical-stage pharmaceutical company focused on developing oral therapies for sleep-related breathing diseases, with an emphasis on obstructive sleep apnea. Its lead product candidate, AD109, is an investigational once-daily oral therapy designed to target the underlying neuromuscular dysfunction associated with OSA.
About Apnimed, Inc.
Apnimed, Inc. is a clinical-stage pharmaceutical company focused on developing oral therapies for sleep-related breathing diseases, with an emphasis on obstructive sleep apnea. Its lead product candidate, AD109, is an investigational once-daily oral therapy designed to target the underlying neuromuscular dysfunction associated with OSA. The company’s work centers on advancing medicines that may address mild, moderate, and severe forms of sleep apnea through a simplified pill-based approach. Based in Cambridge, Massachusetts, and founded in 2017, Apnimed operates within the biotechnology and sleep medicine markets, where it contributes to the development of new treatment options for patients with chronic breathing disorders during sleep.
CEO Mr. Kevin Robert Lind · 112 employees · United States · https://apnimed.com